Loading patent…
AssigneeHermann P. T. Ammon
InventorsHermann P.T. Ammon, Hasan Safayhi
Estimating the term…
The invention concerns the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of, normal leucocytic elastase or plasmin activity, in human or veterinary medicine. The invention further concerns the use of pure boswellic acid or a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preparing a medicament for treating diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.
A method for inhibiting the destructive activity of leucocytic elastase or plasmin on functional tissue in a mammal suffering from a disease selected from the group consisting of chronic bronchitis, pulmonary emphysema, acute respiratory distress syndrome (lung shock), cystic fibrosis (mucoviscidosis), glomerulonephritis and rheumatoid arthritis, said method comprising administering to said mammal an active agent which is boswellic acid, a physiologically acceptable salt or derivative thereof, a salt of said derivative, a plant extract containing boswellic acid, or a combination thereof, in an amount effective to inhibit the destructive activity of leucocytic elastase or plasmin on functional tissue.
A method for inhibiting the destruction of functional tissue associated with a disease selected from the group consisting of chronic bronchitis, pulmonary emphysema, acute respiratory distress syndrome (lung shock), cystic fibrosis (mucoviscidosis), glomerulonephritis and rheumatoid arthritis, said disease being caused by increased leucocytic elastase or plasmin activity or being treatable by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering to a mammal in need of such inhibition an active agent which is boswellic acid, a physiologically acceptable salt or derivative thereof, a salt of said derivative, a plant extract containing boswellic acid, or a combination thereof, in an amount effective for inhibiting the destruction of functional tissue.
Dependencies are inferred from the claim text.